A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD

A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD

This study compared the efficacy and safety of once-daily umeclidinium 62.5 µg with once-daily glycopyrronium 50 µg in patients with moderate-to-severe chronic obstructive pulmonary disease. This was a 12-week, multicentre, randomised, open-label, parallel-group study (Clinicaltrials.gov: NCT0223661...

Full description

Bibliographic Details
Main Authors:	Tara Rheault, Sanjeev Khindri, Mitra Vahdati-Bolouri, Alison Church, William A. Fahy
Format:	Article
Language:	English
Published:	European Respiratory Society 2016-04-01
Series:	ERJ Open Research
Online Access:	http://openres.ersjournals.com/content/2/2/00101-2015.full

Similar Items

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD
by: Feldman G, et al.
Published: (2016-04-01)

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
by: François Maltais, et al.
Published: (2019-10-01)

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
by: Claus F. Vogelmeier, et al.
Published: (2017-07-01)

Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study
by: John H. Riley, et al.
Published: (2018-01-01)

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
by: Singh D, et al.
Published: (2016-06-01)

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
by: Dhvani Shah, et al.
Published: (2018-05-01)

COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017-08-01)

Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study
by: Kerwin EM, et al.
Published: (2017-02-01)

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
by: Plate T, et al.
Published: (2020-06-01)

A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 µg on health-related quality of life in patients with COPD
by: Siler TM, et al.
Published: (2016-05-01)

Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients
by: Miravitlles M, et al.
Published: (2016-01-01)

Early and sustained symptom improvement with umeclidinium/vilanterol monotherapy in COPD: a analysis of the EMAX randomised controlled trial
by: Edward M Kerwin, et al.
Published: (2020-05-01)

New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol
by: Cazzola M, et al.
Published: (2013-10-01)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01)

COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017-08-01)

Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study
by: Mehta R, et al.
Published: (2013-03-01)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
by: Anzueto AR, et al.
Published: (2017-05-01)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
by: Buhl R, et al.
Published: (2012-10-01)

Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol
by: Albertson TE, et al.
Published: (2015-02-01)

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
by: Albertson TE, et al.
Published: (2019-06-01)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
by: Gong S, et al.
Published: (2021-02-01)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
by: Buhl R, et al.
Published: (2014-03-01)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
by: D&rsquo;Urzo A
Published: (2013-08-01)

The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD
by: James Dean, et al.
Published: (2020-12-01)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
by: Antonio R. Anzueto, et al.
Published: (2018-06-01)

Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy
by: Lal C, et al.
Published: (2016-12-01)

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
by: Sandeep Bansal, et al.
Published: (2021-05-01)

Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study
by: Zheng JP, et al.
Published: (2015-09-01)

Glycopyrronium bromide is a new long-acting anticholinergic drug for the treatment of COPD
by: S. N. Avdeev, et al.
Published: (2014-12-01)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
by: Horita N, et al.
Published: (2015-04-01)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
by: Ridolo E, et al.
Published: (2019-01-01)

A novel model-based approach for dose determination of glycopyrronium bromide in COPD
by: Arievich Helen, et al.
Published: (2012-12-01)

Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
by: Mantero M, et al.
Published: (2018-07-01)

Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
by: Sundeep Salvi, et al.
Published: (2021-07-01)

Effects of combination therapy indacaterol/glycopyrronium versus tiotropium on moderate to severe COPD: evaluation of impulse oscillometry and exacerbation rate
by: Antonio Molino, et al.
Published: (2017-09-01)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
by: Vincken W, et al.
Published: (2014-02-01)

Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
by: Molino A, et al.
Published: (2018-06-01)

The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study
by: Requena G, et al.
Published: (2021-03-01)

Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
by: Chaoying Hu, et al.
Published: (2015-01-01)

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
by: Vogelmeier C, et al.
Published: (2016-12-01)